Lindahl advises Senzime AB on a directed new share issue of SEK 100 million

Lindahl has advised Senzime AB (publ) in connection with a directed new share issue that will provide the company with SEK 100 million before transaction costs.

The subscription price was determined through an accelerated bookbuilding process, with Carnegie Investment Bank acting as financial adviser.

About Senzime

Senzime AB is a company listed on Nasdaq Stockholm that develops and markets CE and FDA approved monitoring systems for patients undergoing anaesthesia.

Lindahl's team consisted of Mattias Prage, Andreas Mellberg and Michaela Larsson.

Do you want to know more? Contact:

Mattias Prage

Partner | Advokat

Michaela Larsson

Associate | Advokat

Andreas Mellberg

Counsel | Advokat